Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.

Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J.

J Nucl Med. 2012 Jul;53(7):1155-63. doi: 10.2967/jnumed.111.098624. Epub 2012 Jun 14. Erratum in: J Nucl Med. 2016 Jun;57(6):988.

2.

Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.

Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, Hawkins RA, Veatch J, Hasegawa B.

J Nucl Med. 2001 Nov;42(11):1713-21.

3.

Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.

Modak S, Zanzonico P, Carrasquillo JA, Kushner BH, Kramer K, Cheung NK, Larson SM, Pandit-Taskar N.

J Nucl Med. 2016 Feb;57(2):231-7. doi: 10.2967/jnumed.115.161752. Epub 2016 Jan 7.

PMID:
26742708
4.

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.

Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D.

J Clin Oncol. 1998 Jan;16(1):229-36.

PMID:
9440747
5.

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM.

J Clin Oncol. 2006 Jan 20;24(3):500-6.

6.

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.

Gaze MN, Chang YC, Flux GD, Mairs RJ, Saran FH, Meller ST.

Cancer Biother Radiopharm. 2005 Apr;20(2):195-9.

PMID:
15869455
7.

Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial.

DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian F, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca JG, Matthay KK.

Clin Cancer Res. 2012 May 1;18(9):2679-86. doi: 10.1158/1078-0432.CCR-11-3201. Epub 2012 Mar 15.

8.

Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.

Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM.

J Clin Oncol. 2009 Mar 1;27(7):1020-5. doi: 10.1200/JCO.2007.15.7628. Epub 2009 Jan 26.

9.

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM.

J Clin Oncol. 2007 Mar 20;25(9):1054-60.

10.

Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.

DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charron M, Hawkins R, Matthay KK.

J Clin Oncol. 2004 Jun 15;22(12):2452-60.

11.

131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.

French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K.

Pediatr Blood Cancer. 2013 May;60(5):879-84. doi: 10.1002/pbc.24351. Epub 2012 Sep 28.

PMID:
23024113
12.

Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.

Monsieurs MA, Thierens HM, Vral A, Brans B, De Ridder L, Dierckx RA.

Nucl Med Commun. 2001 Apr;22(4):367-74.

PMID:
11338046
13.

Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.

Kang TI, Brophy P, Hickeson M, Heyman S, Evans AE, Charron M, Maris JM.

J Pediatr Hematol Oncol. 2003 Oct;25(10):769-73.

PMID:
14528098
14.

Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.

Bleeker G, Schoot RA, Caron HN, de Kraker J, Hoefnagel CA, van Eck BL, Tytgat GA.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1711-7. doi: 10.1007/s00259-013-2510-z. Epub 2013 Aug 7.

15.

Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma.

Buckley SE, Chittenden SJ, Saran FH, Meller ST, Flux GD.

J Nucl Med. 2009 Sep;50(9):1518-24. doi: 10.2967/jnumed.109.064469.

16.

Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).

Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK.

Eur J Cancer. 2015 Nov;51(16):2465-72. doi: 10.1016/j.ejca.2015.07.023. Epub 2015 Aug 5.

PMID:
26254811
17.

Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).

Trieu M, DuBois SG, Pon E, Nardo L, Hawkins RA, Marachelian A, Twist CJ, Park JR, Matthay KK.

Pediatr Blood Cancer. 2016 Mar;63(3):436-42. doi: 10.1002/pbc.25816. Epub 2015 Oct 27.

PMID:
26506090
18.

Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma.

Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, Damon L, Linker C, Sznewajs A, Shiboski S, Fitzgerald P.

J Clin Oncol. 2009 Sep 1;27(25):4162-8. doi: 10.1200/JCO.2008.21.3496. Epub 2009 Jul 27.

19.

High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.

Toporski J, Garkavij M, Tennvall J, Ora I, Gleisner KS, Dykes JH, Lenhoff S, Juliusson G, Scheding S, Turkiewicz D, Békássy AN.

Biol Blood Marrow Transplant. 2009 Sep;15(9):1077-85. doi: 10.1016/j.bbmt.2009.05.007. Epub 2009 Jul 8.

20.

131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.

Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK.

Biol Blood Marrow Transplant. 2015 Apr;21(4):673-81. doi: 10.1016/j.bbmt.2014.12.008. Epub 2015 Jan 30.

Items per page

Supplemental Content

Write to the Help Desk